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Protective, CD8þ T Cell-Mediated Immunity Against
Leishmania Major
Katharina Kronenberg1, Sven Brosch1, Florian Butsch1, Yayoi Tada2,3, Naotaka Shibagaki2,4, Mark C. Udey2
and Esther von Stebut1
In murine leishmaniasis, healing is mediated by IFN-g-producing CD4þ and CD8þ T cells. Thus, an efficacious
vaccine should induce Th1 and Tc1 cells. Dendritic cells (DCs) pulsed with exogenous proteins primarily induce
strong CD4-dependent immunity; induction of CD8 responses has proven to be difficult. We evaluated
the immunogenicity of fusion proteins comprising the protein transduction domain of HIV-1 TAT and the
Leishmania antigen LACK (Leishmania homolog of receptors for activated C kinase), as TAT-fusion proteins
facilitate major histocompatibility complex class I-dependent antigen presentation. In vitro, TAT–LACK-pulsed
DCs induced stronger proliferation of Leishmania-specific CD8þ T cells compared with DCs incubated with
LACK alone. Vaccination with TAT–LACK-pulsed DCs or fusion proteins plus adjuvant in vivo significantly
improved disease outcome in Leishmania major-infected mice and was superior to vaccination with DCs treated
with LACK alone. Vaccination with DCþ TAT–LACK resulted in stronger proliferation of CD8þ T cells when
compared with immunization with DCþ LACK. Upon depletion of CD4þ or CD8þ T cells, TAT–LACK-mediated
protection was lost. TAT–LACK-pulsed IL-12p40-deficient DCs did not promote protection in vivo. In summary,
these data show that TAT-fusion proteins are superior in activating Leishmania-specific Tc1 cells when compared
with antigen alone and suggest that IL-12-dependent preferential induction of antigen-specific CD8þ cells
promotes significant protection against this important human pathogen.
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INTRODUCTION
Infections with Leishmania spp. are among the most frequent
infectious diseases worldwide with more than 12 million
people affected (Sacks and Noben-Trauth, 2002; Murray
et al., 2005). Although 350 million people are at risk of
infection every day, an efficacious vaccine does not exist
(Murray et al., 2005). The important role of IFN-g-producing,
Leishmania-specific CD4þ T cells in protective immunity
against Leishmania major in mice is well established (Reiner
and Locksley, 1995; Sacks and Noben-Trauth, 2002). IFN-g
activates infected host macrophages to produce NO and to
efficiently eliminate parasites. Control of disease and
long-lasting immunity in mice is thus associated with
Th1-predominant immunity, whereas development of Th2
responses, as observed in BALB/c mice, leads to progressive
disease (Reiner and Locksley, 1995; Sacks and Noben-Trauth,
2002). Infections of C57BL/6 mice serve as a surrogate model
for self-healing cutaneous leishmaniasis of humans. Although
mixed antigen-specific Th1/Th2 immune responses are
observed in the peripheral blood of humans, lesional
cytokine profiles clearly revealed that IFN-g is associated
with lesion resolution, whereas elevated IL-4/IL-10 levels
were found in more progressive, nonhealing disease
(Kharazmi et al., 1999; van Weyenbergh et al., 2004; Saha
et al., 2006; Geiger et al., 2010). Several studies using the
physiologically relevant murine low-dose model have indi-
cated that IFN-g release by CD8þ L. major-specific T cells
(Tc1) also promotes the development of protective immunity
(Muller et al., 1991; Belkaid et al., 2002; Uzonna et al., 2004).
Development of Th1/Tc1 immunity requires IL-12, which
is released by infected (e.g., skin-derived) dendritic cells
(DCs) (Flohe et al., 1998; von Stebut et al., 1998, 2000; Ahuja
et al., 1999; Ritter and Osterloh, 2007; von Stebut, 2007).
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Upon infection, DCs become activated and efficiently
present Leishmania antigen to CD4 and CD8 cells (Sacks
and Noben-Trauth, 2002). Interestingly, restimulation of
Leishmania-specific CD8þ T cells was possible only when
L. major-containing DCs and not other antigen-presenting
cells (i.e., infected macrophages) were used (Belkaid et al.,
2002). In addition, infection studies with ovalbumin (OVA)-
transgenic parasites showed that proteins released by
L. major in infected DCs are a major source of peptides for
the generation of parasite-specific CD8þ T cells (Bertholet
et al., 2005). Thus, DCs infected with viable parasites present
antigen in the context of both the major histocompatibility
complex (MHC) class I and II and promote induction of Th1/
Tc1-dependent protective immunity.
The development of an effective anti-Leishmania vaccine
has yet to be realized. Vaccination approaches include
whole-killed or subunit vaccines with adjuvants, genetically
attenuated Leishmania parasites, Leishmania peptides ex-
pressed in attenuated organisms (e.g., Bacillus Calmette
Gue´rin), DNA vaccines, and DC agonists (CpG motifs,
Flt-3 (FMS-like tyrosine kinase 3) ligand) (Vanloubbeeck
and Jones, 2004). Most of these approaches have shown
some efficacy in murine models, but may be difficult to
implement in humans for different reasons (ethical, non-
effectiveness in humans, side effects, and so on). Utilization
of recombinant peptides/proteins or DNA encoding these
antigens represent promising approaches, as in the case of
live parasites the risk of reactivation in immunosuppressed
patients (e.g., those coinfected with strains inducing visceral
disease and HIV) is problematic. Some studies have
suggested that persisting viable parasites (perhaps residing
in DCs) are required for long-lasting immunity (Moll et al.,
1995; Belkaid et al., 2001). Previously, however, it was
shown that although effector cells are lost upon complete
eradication of parasites, central memory T cells mediate
long-term immunity to L. major in the absence of
persistent parasites (Zaph et al., 2004). These results support
continued emphasis on development of a protein/peptide-
based vaccine.
Several Leishmania vaccines have used DCs pulsed with
parasite lysates (Flohe et al., 1998; Ahuja et al., 1999;
Ramirez-Pineda et al., 2004) or recombinant parasitic
proteins (Berberich et al., 2003). However, protein-pulsed
DCs were not as efficient in promoting protection as were
DCs infected with viable parasites (von Stebut et al., 2000).
We previously purified recombinant model tumor-associated
antigens containing the HIV TAT protein transduction domain
(PTD) (Shibagaki and Udey, 2002, 2003). The PTD promotes
accumulation of protein in the cytosol of cells independent of
endocytosis (Wadia and Dowdy, 2005). This fusion protein
efficiently transduced DCs and was processed by protea-
somes for MHC class I-dependent presentation to cytotoxic
T lymphocytes (Shibagaki and Udey, 2002, 2003). In
addition, TAT-containing antigen was also presented to
CD4 T cells as efficiently as native antigen. Finally, TAT-
antigen-transduced DCs induced antigen-specific cytotoxic
T lymphocytes in vivo and vaccinated against tumors
(Shibagaki and Udey, 2002, 2003).
We have now translated this vaccination strategy into a
vaccine against leishmaniasis in C57BL/6 mice. We used the
Leishmania-specific antigen LACK (Leishmania homolog of
receptors for activated C kinase), which is highly conserved
among related Leishmania species and is expressed in both
promastigote and amastigote forms of the parasite (Mougneau
et al., 1995). When compared with LACK alone, TAT–LACK
fusion protein was superior in inducing parasite-specific
CD8þ T cells and in vaccinating against murine L. major
infections.
RESULTS
Generation of fusion proteins comprising the HIV-1 TAT and
LACK
Plasmids encoding TAT PTD-containing and control proteins
(analogous to those generated previously using OVA;
Shibagaki and Udey, 2002) were engineered, and recombi-
nant proteins were expressed in E. coli, purified using Ni2þ
affinity chromatography, dialyzed against phosphate-buffered
saline (PBS), and separated using 4–12% SDS-PAGE gels
(Figure 1a). The purified LACK protein was smaller than
TAT–LACK as expected.
Generation and protein transduction of DCs
Bone marrow-derived DCs (BMDCs) have previously been
used for vaccination against Leishmania infections (Ahuja
et al., 1999; Berberich et al., 2003; Ghosh et al., 2003;
Ramirez-Pineda et al., 2004). We generated DCs by culturing
bone marrow of C57BL/6 mice with GM-CSF and IL-4 (Inaba
et al., 1992). One representative flow cytometric analysis
showing the phenotype and purity of the immature DCs
harvested on day 6 is provided in Figure 1b. DCs strongly
expressed MHC class II and CD11c as well as intermediate
and low levels of CD86 and CD40, respectively, consistent
with their immature state.
Recombinant fusion proteins were treated with polymyxin
B before addition to DCs. Protein transduction was performed
by incubating 2105 DCs with various concentrations
(0.3–3 mM) of fusion or control proteins as described
(Shibagaki and Udey, 2002). Cytosolic distribution of
TAT–LACK when compared with LACK was confirmed using
confocal microscopy (Shibagaki and Udey, 2002). Protein
transduction itself did not lead to significant alterations of
MHC class II/costimulatory molecules when compared with
untreated DCs or induction of IL-12 release (Figure 1c).
DCs pulsed with TAT-containing fusion protein efficiently prime
and restimulate antigen-specific CD8þ T cells
To assess the potential of fusion protein-pulsed DCs to
restimulate antigen- specific primed T cells, we first isolated
Thy1.2þ T cells (purity 484%) from mice infected for X6
weeks with L. major. BMDCs were either pulsed with antigen
(2 mM protein) or were infected with L. major (5:1 amastigote/
DC ratio; mean infection rate 38±2%) for 18 hours. DCs
were subsequently irradiated and cocultured with carboxy-
fluorescein diacetate succinimidyl ester (CFSE)-labeled
T cells for 5 days. Antigen-specific expansion was quantified
by determining the percentage of proliferating T cells after
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subtracting baseline proliferation induced with unpulsed DCs
(Figure 1d). Results combined from two to three independent
experiments are shown. TAT–LACK- and LACK-pulsed DCs
induced proliferation of CD4þ T cells, but less vigorously
than DCs infected with live parasites. Differences between
TAT–LACK and LACK in CD4þ cells were not statistically
significant. In contrast, more efficient restimulation of CD8þ
T cells was achieved with TAT–LACK-pulsed DCs when
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Figure 1. Dendritic cells (DCs) pulsed with TAT–LACK are superior in priming and restimulation of antigen-specific CD8þ T cells when compared with
LACK DCs. (a) Coomassie blue-stained 4–12% SDS-PAGE gel in which purified TAT–LACK and LACK were resolved. (b) Bone marrow-derived, immature DCs
were generated with rIL-4 and rGM-CSF (10 ng ml–1) and harvested as immature DCs on day 6. Expression of activation markers was analyzed by flow cytometry
using monoclonal antibodies against CD40, CD86, and MHC class II as well as rat anti-mouse IgG2a (R2a) and hamster anti-mouse IgG1 (HIgG) as isotype
controls. One representative FACS staining is shown. (c) DCs were pulsed for 18 hours with TAT–LACK (TL) or LACK (L), or left untreated. IL-12p40 release was
determined by ELISA (mean±SEM, nX3). (d) TAT–LACK (DCTL)-treated and LACK (DCL)-treated DCs were obtained or DCs were infected with L. major
amastigotes (DCinf, ratio 1:5). T cells were enriched from 6-week L. major-infected C57BL/6 mice using anti-Thy1.2-coated microbeads, labeled with CFSE, and
restimulated with irradiated, antigen-pulsed or infected DCs (1:10 ratio of DC/T cells, 1106 per 200 ml). T-cell proliferation was determined after 5 days using
flow cytometry. (e) C57BL/6 mice were vaccinated with 2 105 untreated DCs, DCinf, DCTL, or DCL. After 1 week, lymph node (LN) cells were isolated, labeled
with carboxyfluorescein diacetate succinimidyl ester (CFSE), and antigen-specific proliferation was determined by FACS after 5 days of subculture in the
presence of soluble Leishmania antigen (SLA). T cells were pregated using staining for CD4 or CD8. (d, e) For each mouse, the relative number of Leishmania-
reactive cells (in percentage of total CD4þ or CD8þ T cells) was calculated when compared with untreated control cultures (mean±SEM, nX3, *Pp0.05, and
**Pp0.005 when compared with DC alone; *above lines indicate differences between stimulation groups).
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compared with LACK-pulsed DCs (8.3±1.6 vs. 2.3±0.9%,
respectively, nX3, Pp0.05).
In addition to T-cell expansion, we assessed the cytokine
profile of CD4 and CD8 T cells after restimulation of
TAT–LACK- or LACK-pulsed DCs (Table 1). CD4 or CD8 T
cells were isolated from infected mice. T cells were plated at
106 per 200ml and restimulated with irradiated, untreated,
protein-pulsed, or infected DCs (105 per 200 ml). Cytokine
release from T cells was assessed after 48 hours using ELISA
specific for IFN-g and IL-4. Irradiated DCs did not release
IFN-g, IL-4, or IL-10 (data not shown). When compared with
unpulsed DCs, infected DCs and DCþ TAT–LACK induced
significant IFN-g release from CD4 cells. The IFN-g/IL-4 ratios
revealed that infected and TAT–LACK-pulsed DCs both
induced an IFN-g-predominant Th1 cytokine profile. Inter-
estingly, LACK-pulsed DCs did not promote IFN-g release
from primed CD4 cells, confirming previous data that LACK-
responsive CD4 cells primarily produce IL-4 (Mougneau
et al., 1995). In parallel, CD8 cells restimulated with infected
DCs or DCþTAT–LACK released higher amounts of IFN-g
when compared with cells stimulated with unpulsed DCs or
DCs pulsed with LACK alone. Significant differences in IL-10
levels in the supernatants were not observed.
We next sought to determine whether preferential induc-
tion of antigen-specific CD8þ T cells (in addition to CD4
cells) could be achieved by in vivo vaccination of mice with
antigen-pulsed DCs (Figure 1e). BMDCs were pulsed over-
night with 333mM of TAT–LACK or LACK in the presence of
polymyxin B or infected with amastigotes of L. major (ratio
1:5, mean infection rates after 18 hours 27±3%). Cells were
harvested, washed, counted, and injected intradermally into
the ear skin of naive mice (2 105 cells per 50 ml per ear).
After 1 week, lymph node (LN) cells were harvested, labeled
with CFSE, and restimulated with soluble Leishmania antigen
(SLA, 25 mg ml–1) or staphylococcal enterotoxin B (10 mg ml–1)
as a control (data not shown). Antigen-specific expansion of
CD4þ and CD8þ T cells was assessed 5 days after
restimulation. Impaired proliferation of T cells was not found
in any of the vaccination groups as assessed by stimulation
with superantigen. Both DCþ LACK and DCþTAT–LACK
induced priming of antigen-specific CD4þ T cells to a similar
degree, suggesting that the level of LACK uptake by DCs per
se was similar. Protein-pulsed DCs did not induce responses
to the extent observed with DCs infected with live parasites.
DCþTAT–LACK induced clear CD8 priming as did infected
DCs. Most importantly, TAT–LACK-pulsed DCs more effi-
ciently primed CD8þ T cells in vivo when compared with
DCs pulsed with LACK alone (4.5±1.5 vs. 0%, respectively,
nX4, Pp0.05).
Vaccination with TAT–LACK-pulsed DCs is superior to DCs
pulsed with LACK alone
We next investigated the vaccination potential of fusion
protein-pulsed DCs in Leishmania-resistant C57BL/6 mice
in vivo. LACK reactivity of naive CD4þ T cells has been
detected in C57BL/6 mice (Sacks and Noben-Trauth, 2002).
Data generated with Leishmania-resistant mice might be most
relevant to a clinical setting because the course of disease in
C57BL/6 mice most closely mimics natural L. major infec-
tions of humans.
At 1 week before infection, C57BL/6 mice were vacci-
nated with 2 105 DCs pulsed with fusion protein, LACK
alone, or irrelevant controls (DC alone, DC plus TAT-b-
galactosidase (bgal), or bgal; Figure 2). Mice were infected
into contralateral ears with either high-dose (2105 para-
sites, Figure 2a) or low-dose inocula (Figure 2b–f), and lesion
development was assessed weekly. In both high- and low-
dose infections, vaccination with TAT–LACK-pulsed DCs was
more efficacious than vaccination with DCs pulsed with
LACK alone. This effect was most pronounced in low-dose
infections (Figure 2b). Vaccination with irrelevant controls or
unpulsed DCs did not have an effect on lesion development
Table 1. Cytokine responses of restimulated T cells after incubation with TAT–LACK- or LACK-pulsed DCs
Restimulation of antigen-specific C57BL/6 T cells w/ DC DCinfected DCTATLACK DCLACK
CD4
IFN-g (pg ml–1) 20±20 7,236±230*** 973±370+,* 31±31
IL-4 (pg ml–1) 5±3 107±58 1±1 7±4
IFN-g/IL-4 7±7 317±163 681±60+++,*** 2±2
IL-10 (pg ml–1) 426±90 631±287 534±190 520±232
CD8
IFN-g (pg ml–1) 777±777 4,914±1,754 1,556±1,032 360±360
IL-4 (pg ml–1) 2±1 20±7* 28±1 11±9
IFN-g/IL-4 777±777 225±126 260±17+++ 121±121
IL-10 (pg ml–1) 248±44 278±53 308±109 416±137
Abbreviations: DC, dendritic cell; LACK, Leishmania homolog of receptors for activated C kinase. DC were incubated with TAT–LACK, LACK, or infected
(infection rate 25±4%, nX3) as described in Materials and Methods. CD4+ or CD8+ cells were isolated from X5-week infected mice, plated at 9 105 per
200 ml, and restimulated with DCs (1 105) for 48 hours. Cytokine content of supernatants was determined by ELISA (mean±SEM; pooled data from three
independent experiments; nX3 mice per group; statistical comparisons are provided against DC alone (*) or DCLACK (
+)). +,*Pp0.05, and +++,***Pp0.002.
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when compared with unvaccinated mice (Figure 2c). Smaller
lesion sizes in DCþTAT–LACK-vaccinated mice paralleled
significantly decreased lesional parasite burdens (Figure 2d).
In week 7 after infection, ears of mice vaccinated
with TAT–LACK contained 4.5±0.9102 parasites when
compared with LACK-DC-treated groups (5.1±1.1103
parasites, nX6, Pp0.005).
In a previous report, pretreatment of antigen-pulsed DCs
with CpG oligonucleotides (ODNs) further promoted protec-
tion (independent of DC-derived IL-12 production; Ramirez-
Pineda et al., 2004). In our model, cotreatment with 10 mg
CpG ODN 1826 injected into vaccination sites did not have
an adjuvant effect on disease outcome (data not shown).
Successful vaccination with fusion-protein-pulsed DCs is IL-12
dependent
Induction of Th1/Tc1-dependent protection against Leishma-
nia infections is critically dependent on the release of IL-12
from infected DCs (Sacks and Noben-Trauth, 2002). We thus
determined whether release of IL-12 from protein-pulsed DCs
is important for the efficacy of our vaccination approach.
BMDCs were generated from C57BL/6 IL-12p40/ or wild-
type controls. Characterization of IL-12p40/ and wild-type
DCs revealed no differences in expression of CD11c, MHC
class II, as well as the costimulatory molecules CD40 and
CD86, as determined by flow cytometry (data not shown).
DCs were pulsed overnight with antigen. Similar to previous
experiments, mice were vaccinated and infections were
initiated 1 week later by inoculation of 103 metacyclic
promastigotes into contralateral ears (Figure 2 e and f).
TAT–LACK-pulsed IL-12p40-deficient DCs failed to protect
vaccinated mice from L. major infection (Figure 2f). Thus,
release of IL-12p40 from DCs is required for TAT–LACK-
mediated immunity against L. major.
Utilization of TAT–LACK for direct in vivo vaccination
Generation/isolation of DCs ex vivo from humans is laborious
and expensive and will not be feasible in Leishmania-
endemic countries. We thus initiated studies analyzing the
potential of a TAT–LACK fusion protein vaccine directly
in vivo to circumvent ex vivo protein transduction of DCs.
First, the ability of the direct protein vaccine to induce
antigen-specific T-cell responses in vivo was assessed. Mice
were vaccinated with TAT–LACK, LACK, irrelevant TAT-OVA,
or SLA on days 7 and 6. Subsequently, 10mg of CpG ODN
1826 was administered into the same ears on day 5. On day
0, LN cells were isolated, labeled with CFSE, and restimulated
with 25mg ml–1 SLA. Antigen-specific expansion of CD4þ and
CD8þ T cells was assessed 4 days after restimulation (Figure
3a and b). Despite the fact that the induction of antigen-
specific T cells was weaker with protein when compared with
the DC-based vaccine (compare Figure 1e) as expected,
TAT–LACK-mediated T-cell priming was stronger than that by
LACK alone for both CD4 and CD8 cells.
We next attempted to vaccinate with TAT–LACK fusion
proteins directly in vivo. TAT–LACK and LACK were adminis-
tered intradermally into ear skin for two consecutive days
(10mg per ear), and infections with 103 metacyclic promasti-
gotes were initiated 2 weeks later. When compared with PBS-
treated control mice, no protective effect was observed (data
not shown). Next, recombinant fusion proteins were adminis-
tered for 2 days followed by a single injection of CpG ODN
1826 (10mg per ear; Zimmermann et al., 1998; Stacey and
Blackwell, 1999; Walker et al., 1999) as adjuvant on day 12
(Figure 3c). Irrelevant (fusion) proteins plus CpG ODN 1826
were included as controls (data not shown). Interestingly, only
TAT–LACKþCpG ODN significantly prevented disease pro-
gression of infected C57BL/6 mice, whereas controls were
ineffective. As shown for the DC-based vaccination approach,
TAT–LACK-mediated protection was always superior to LACK
alone (e.g., 4±0.6 vs. 13±2.6 mm3 in week 7 after infection,
respectively, nX12, Pp0.002).
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Figure 2. Improved disease outcome after vaccination with fusion protein-
pulsed dendritic cells (DCs). DCs were generated from IL-12p40/ (f) or
wild-type C57BL/6 (a–f) mice and pulsed overnight with TAT–LACK (DCTL),
LACK alone (DCL), TAT-bgal (DCTbgal), or bgal (DCbgal). Protein-pulsed DCs
(2105) were injected intradermally into the ear skin of C57BL/6 mice. After
1 week, mice were infected with 2 105 (a) or 103 (b–f) metacyclic
promastigotes of L. major. (a–c, e, f) Lesion volumes were assessed every week
using a caliper (mean±SEM, nX4, statistical differences with unvaccinated
groups (*) and with LACK-pulsed DCs (þ ) are shown, *,þPp0.05,
**,þ þPp0.005, and ***,þ þ þPp0.002). (d) Lesional parasite loads of
vaccinated C57BL/6 mice were determined by limiting dilution assays. DCs
were infected with amastigotes of L. major (parasite/cell ratio 5:1). Each data
point represents the number of organisms from one ear and the bars indicate
arithmetic means. Pooled data of two independent experiments are shown
(nX6; *Pp0.05 and **Pp0.005).
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The vaccination efficacy of TAT–LACK fusion protein is
dependent on both CD4 and CD8 cells
To assess the dependence of the efficacy of TAT–LACK
as a vaccine on CD4 and CD8 cells, we performed
depletion experiments in vivo. To ensure that T cells were
depleted only during vaccination, extensive dose-response
experiments were performed. To achieve sufficient depletion,
125mg of anti-CD4 mAb (clone GK1.5) or 50 mg of anti-CD8
(clone 2.43) were injected 2 days before vaccination. As a
control, some mice were treated with an irrelevant isotype
control antibody. The T-cell depletion efficacy was deter-
mined on the day of vaccination. The frequency of CD4þ
and CD8þ cells in peripheral blood of anti-CD4- and anti-
CD8-treated mice was 0.05 and 0.9%, respectively. Full
restoration of the T-cell compartment was confirmed by flow
cytometry from peripheral blood before mice were infected
with low-dose inocula of L. major (day 21 after vaccination).
Interestingly, if either CD4 or CD8 T cells were depleted
during vaccination, the vaccination success of TAT–LACK
was completely abrogated, as manifested by lesion volumes
(Figure 3c).
DISCUSSION
Protective immunity against L. major is dependent on both
Th1- and Tc1-dependent immunity. In this study we have
used fusion proteins comprising the 11aa PTD from HIV-1
TAT and LACK. We showed that vaccination with fusion
proteins containing TAT was consistently superior in promot-
ing protection against cutaneous leishmaniasis when com-
pared with proteins without TAT. Thus, in these proof-of-
principle experiments, we have shown that intentional
induction of antigen-specific CD8þ T cells using TAT-fusion
proteins, in addition to CD4þ T cells, is beneficial for
protection against this important pathogen.
Although infected (skin-derived) DCs seem to be the
critical cells for the induction and maintenance of protective
immunity against L. major (Flohe et al., 1998; von Stebut
et al., 1998, 2000; Ahuja et al., 1999; Sato et al., 2000;
Lemos et al., 2004; Iezzi et al., 2006), use of protein-loaded
DCs showed only limited results when compared with cells
infected with live parasites (Berberich et al., 2003; Ramirez-
Pineda et al., 2004). Parasites and protein enter DCs in
different ways. Parasite internalization results from FcgRI/III-
mediated phagocytosis (Woelbing et al., 2006), whereas
protein uptake is the result of endocytosis. Importantly, FcgR-
mediated parasite uptake facilitates MHC class I and II
antigen processing, whereas protein endocytosis favors MHC
class II-predominant antigen presentation (Amigorena, 2002;
Belkaid et al., 2002; Woelbing et al., 2006). Thus, inefficient
induction of CD8 T cells (rather than suboptimal CD4
priming) may be responsible for the inability of protein-
pulsed DCs to promote effective and long-term antiparasite
immunity when compared with infected DCs. This concept is
supported by our finding that vaccination with DCþ LACK
induced comparable CD4 priming as did DCþTAT–LACK,
whereas CD8 priming was weaker in mice vaccinated with
DCs pulsed with LACK protein alone.
The role of antigen-specific CD4þ T cells in protective
immunity is well established (Reiner and Locksley, 1995;
Sacks and Noben-Trauth, 2002). Additional studies have
highlighted the important role that Leishmania-specific
CD8þ Tc1 cells have in mediating protection, especially in
the physiologically more relevant low-dose infection model
mimicking natural transmission of L. major by sand flies, but
not in high-dose infections (Muller et al., 1991; Erb et al.,
1996; Belkaid et al., 2002; Uzonna et al., 2004). In addition,
previous experiments using DNA-vaccination approaches
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Figure 3. Efficacious vaccination with fusion proteins directly in vivo
depends on both CD4þ and CD8þ T cells. (a, b) C57BL/6 mice were
vaccinated with 10 mg TAT–LACK (TL) or appropriate controls into ears on day
7/6 followed by 10 mg CpG 1826 on day 5. On day 0, draining lymph
node (LN) cells were harvested, single-cell suspensions were prepared, and
cells were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE;
1mM). Labeled cells were plated at 1 106 cells per 200 ml and stimulated
with antigen. After 4 days, cells were harvested and T-cell proliferation was
analyzed by FACS using antibodies against CD4 and CD8. The relative
number of Leishmania-reactive cells per mouse (%) was calculated when
compared with untreated control cultures (mean±SEM, n¼ 3). (c) C57BL/6
mice (5 mice per group) were injected with anti-CD4, anti-CD8, or irrelevant
control mAb (i.p.) and vaccinated twice with 10 mg TL or LACK intradermally
into the ear skin. CpG oligonucleotide (ODN) 1826 was administered the
following day (10 mg per ear). After 3 weeks, after complete restoration of
T cells, mice were infected with 1,000 metacyclic promastigotes of
L. major. Lesion development was monitored weekly in three dimensions and
expressed as mean±SEM (pooled data from three independent experiments
are shown, nX9, statistical differences with unvaccinated groups are shown,
*Pp0.05, and ***Pp0.002).
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induced CD8-dependent protection, which led to efficient
protection (Gurunathan et al., 1997). In this study we showed
that induction of both LACK-reactive CD4 and CD8 T cells
contributed to protection against L. major infection after
vaccination with TAT–LACK fusion protein. In a previous
study, DCs transduced with HIV TAT-PTD-containing whole
protein antigens also stimulated both antigen-specific CD8þ
and CD4þ T cells (Mitsui et al., 2006). Thus, the superiority
of TAT–LACK-pulsed DCs likely relates to their ability to
induce CD8 priming in addition to CD4 priming, which was
also achieved by LACK-treated DCs. This confirms the results
of previous studies that showed that CD8þ T cells are critical
for protection using LACK as the vaccinating antigen
(Gurunathan et al., 1997, 2000; Shah et al., 2003; Dondji
et al., 2008).
LACK has been found to be the focus of the early immune
response directed against the parasites, with most LACK-
reactive T cells producing IL-4, but not IFN-g (Mougneau
et al., 1995). LACK-induced preferential expansion of
parasite-specific Th2 cells and a low level of IFN-g
production result in progressive infection of BALB/c mice
and fatal outcome (Heinzel et al., 1989). It is accepted that
C57BL/6 mice are by far the better model than BALB/c mice
to investigate vaccines with potential relevance for human
infections. However, as a reaction status similar to that in
BALB/c mice may occur in some humans, the effects of the
vaccination procedure described in this study were also
assessed in susceptible BALB/c mice (data not shown). Using
TAT-fusion proteins in both DC- and protein-based vaccines,
TAT–LACK-treated BALB/c mice were significantly protected
against progressive infection with L. major, as manifested by
clearly reduced lesion volumes and parasite burdens. Similar
to the findings reported in this study, TAT–LACK was superior
to LACK, and TAT–LACK-mediated protection was dependent
on CD4þ as well as CD8þ T cells. LACK may not be the
optimal antigen choice for vaccinations. Previous experi-
ments confirmed that LACK-pulsed DCs did not efficiently
promote protection relative to that observed with other
Leishmania-derived antigens (Berberich et al., 2003). At-
tempts to modify the immune response to the large LACK
protein by using different epitopes have been successful
(Jensen et al., 2009). Thus, it is reasonable to predict that if an
optimized antigen combination (such as certain LACK
peptides or other antigens capable of inducing more Th1/
Tc1-prone immunity) was used for TAT-fusion protein-based
vaccinations, the results may be even more promising.
In this study, fusion protein as well as LACK alone did not
promote protection directly in vivo, confirming previous
studies using proteins without adjuvant (Mougneau et al.,
1995; Berberich et al., 2003; Shah et al., 2003; Ramirez-
Pineda et al., 2004). Activation of skin DCs and IL-12
synthesis is required as achieved in vivo by coadministration
of adjuvants such as CpG motifs or others (Zimmermann
et al., 1998; Walker et al., 1999; Shah et al., 2003). In
addition, we also showed that the vaccination efficacy of DCs
pulsed with TAT–LACK was dependent on the production of
IL-12 from the DCs, confirming previous results (Berberich
et al., 2003). Independent of exogenous DCs, TAT–LACK
fusion protein together with CpG efficiently induced protec-
tion against progressive leishmaniasis directly in vivo. TAT–
LACK was consistently superior to LACK alone. These
latter results are important, because DC-based vaccination
approaches will not be widely applicable.
In summary, in this proof-of-principle study, we have
shown that induction of Leishmania-specific CD8þ T cells, in
addition to CD4þ cells, is beneficial for the development of
protective immunity. In both DC- and protein-based vaccina-
tions, immunization with TAT–LACK was superior to injection
of LACK alone. Thus, TAT-fusion proteins represent promis-
ing tools for the induction of protective immunity against not
only cancer, but also infectious diseases with intracellular
pathogens. Future experiments will evaluate in more detail
how this immunization strategy can be improved (e.g., by
studying the durability of its efficacy) and how this vaccina-
tion approach can be translated into humans.
MATERIALS AND METHODS
Generation and characterization of fusion protein
His6-tagged TAT-hemagglutinin (HA)-OVA, HA-OVA, TAT-HA-bgal,
and HA-bgal were obtained and generated as described previously
(Shibagaki and Udey, 2002). Constructs encoding His6-tagged TAT-
HA-LACK were generated by inserting LACK complementary DNA
(þ 427 to þ 939, 170 aa; provided by Dr D Sacks, National Institute
of Allergy and Infectious Diseases, Bethesda, MD) into multiple-
cloning sites (NcoI/EcoRI) of pTAT-HA plasmid in-frame. HA-LACK
constructs were generated by BamHI digestion and religation of
pTAT-HA-LACK plasmids. Plasmids were then transformed into a
RosettaBlue (DE3) competent bacterial strain (Novagen, Merck,
Darmstadt, Germany). For protein extraction, bacterial cell pellets
were sonicated in urea-containing medium. Denatured TAT-HA-
LACK, HA-LACK, TAT-HA-OVA, HA-OVA, TAT-HA-bgal, and HA-
bgal were then purified by sequential Ni2þ nitrilotriacetic acid-
agarose chromatography and dialyzed against PBS as described
(Shibagaki and Udey, 2002). Proteins were stored at 20 1C in PBS/
10% glycerol and thawed immediately before use. SDS-PAGE was
performed with NuPAGE 4–12% Bis-Tris gels and MOPS running
buffer (Shibagaki and Udey, 2002).
Mice and parasites
C57BL/6 mice, 6–8 weeks old, were purchased from the Central
Animal Facility of the University of Mainz. IL-12p40/ C57BL/6
mice were kindly provided by Professor E Schmitt, Department of
Immunology, University of Mainz. All animals were housed in
accordance with institutional and federal guidelines. The experi-
ments were undertaken with approved license from the animal care
and use committee of the Region Rheinland-Pfalz, Germany.
Metacyclic promastigotes or amastigotes of L. major clone VI
(MHOM/IL/80/Friedlin) were prepared as described previously
(Woelbing et al., 2006).
Generation and pulsing of DCs
BMDCs were generated from wild-type or IL-12p40/ mice in GM-
CSF- and IL-4-containing media (32) and harvested on day 6 of cell
culture. The characteristics of the cell populations were assessed by
flow cytometry using relevant surface markers. The following
antibodies were used: anti-I-Ab,d/I-Ed (2G9), anti-CD11c (HL3),
2608 Journal of Investigative Dermatology (2010), Volume 130
K Kronenberg et al.
TAT-Fusion Protein Vaccine Against L. Major
anti-CD40 (3/23), and anti-CD86 (GL1) (all from BD Biosciences/
Becton Dickinson, Heidelberg, Germany). For protein pulsing of
DCs, cells were plated at 1 106 per ml in RPMI/5% fetal calf serum
and recombinant proteins were added at 333 nM up to 2 mM
(Shibagaki and Udey, 2002). Recombinant proteins were treated
with polymyxin B sulfate (50 mg ml–1, Sigma Aldrich, St Louis, MO)
before addition to DCs. After 18 hours of DC pulsing, supernatants
were harvested and cytokine production was analyzed using ELISA
for IL12p40 (R&D Systems, Wiesbaden, Germany).
Restimulation of Leishmania-specific T cells with DCs
T cells were isolated from L. major-infected C57BL/6 mice using
microbeads coated with anti-CD90 (Thy1.2) (Miltenyi, Bergisch-
Gladbach, Germany). T cells (5 106 per ml) were labeled with 1 mM
CFSE (Invitrogen, Karlsruhe, Germany) and subcultured with
irradiated DCs (400 Gy) in a ratio of 10:1 for additional 5 days
(106 cells per 200 ml). Antigen-specific proliferation was assessed
after 5 days using flow cytometry. T cells were selected for
analysis using mAbs against CD4 (L3T4, RM4-5), CD8 (Ly2,
53–6.7), or isotype control mAb (all from BD Biosciences). For each
mouse, the percentage of Leishmania-reactive cells compared with
nonproliferating cells was calculated as described (Woelbing et al.,
2006).
To determine the T-cell cytokine profile after restimulation with
TAT–LACK-transduced DCs, Leishmania-primed T cells were iso-
lated from infected C57BL/6 mice using anti-CD4 and anti-CD8
microbeads (Miltenyi). T cells and DCs were cocultured in a ratio of
10:1 (1 106 cells per 200 ml). After 48 hours of incubation, super-
natants were harvested and cytokine production was assessed using
ELISA for IL-4 (BD Biosciences) and IFN-g (R&D Systems).
Assessing the induction of LACK-reactive T cells in vivo
Groups of X5 C57BL/6 mice were vaccinated in vivo by intradermal
injection of 2 105 protein-pulsed DCs. For the assessment of an
induction of LACK-reactive T cells, LN cells were harvested 1 week
after vaccination of naive mice, labeled with CFSE as described
above, and plated at 106 per 200ml in 96-well U-bottom plates. Cells
were stimulated with SLA or SEB. After 5 days, the frequency of
daughter cells of proliferating antigen-reactive compared with
nonproliferating LN T cells was estimated using flow cytometry
(24). T cells were pregated using staining for CD4 (L3T4, RM4-5),
CD8 (Ly2, 53-6.7), or isotype control mAb (all from BD Biosciences).
The percentage of LACK-reactive cells was calculated separately for
each mouse and the data of three independent experiments were
pooled and expressed as mean±SEM.
Vaccination schedules and L. major infection
Groups of X5 mice were vaccinated with 2 105 per 50 ml
protein-pulsed or untreated DCs injected intradermally into
the ear skin. In some experiments, mice were vaccinated with
fusion proteins dissolved in PBS for two consecutive days
(10 mg per ear) followed by a single injection of CpG ODN 1826
(10 mg per ear). After 1 to 3 weeks, infections were initiated into
contralateral ears by inoculating 2 105 or 103 metacyclic
promastigotes as indicated (Belkaid et al., 2000). In some experi-
ments, anti-CD4 (clone GK1.5, 125 mg per mouse) or anti-CD8
(clone 2.43, 50 mg per mouse) were injected intraperitoneally 2 days
before vaccination.
Disease outcome was determined by assessing lesion volumes,
the number of parasites/lesion, and cytokine profiles of draining LN
cells. Lesion development was assessed weekly in three dimensions
using a caliper, and lesional volumes were reported (in mm3) as
ellipsoids ((a/2 b/2 c/2) 4/3p). Organisms present in lesional
tissue were enumerated using limiting dilution assays (Woelbing
et al., 2006). For measurement of cytokine production, 106
retroauricular LN cells per 200ml were added to 96-well plates in
the presence of SLA (25mg ml–1). Antigen-specific IFN-g (R&D
Systems), IL-4, and IL-10 (BD Biosciences) production was deter-
mined after 48 hours using ELISA.
Statistics
Statistical analysis was performed using the unpaired Student’s t-test.
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